Publication details
Katetrizační ablace fibrilace síní a přímá antikoagulancia
| Title in English | Catheter ablation in atrial fibrillation and direct anticoagulants |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | anticoagulation; atrial fibrillation; ablation; safety |
| Description | Direct anticoagulants (blockers of factor II or factor Xa) have become a routine part of clinical practice and have replaced coumarine blockers (warfarin) in many indications, providing a more beneficial and safer effect. The main indications are non-valvular atrial fibrillation, deep venous thrombosis and lung embolism. New information are available in their uninterrupted use during catheter ablation of atrial fibrillation. The VENTURE AF study has shown non-inferiority of rivaroxaban vs. warfarin in 248 patients undergoing ablation of atrial fibrillation. The RE-CIRCUIT study compared the treatment with dabigatran and warfarin in 704 patients undergoing ablation of atrial fibrillation and has shown a superiority of dabigatran, especially in terms of its safety profile, as dabigatran treatment was associated with lower incidence of bleeding. |